XML 32 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900
Discontinued Operations
 12 Months Ended
Dec. 31, 2015
Discontinued Operations  
Discontinued Operations
13.    Discontinued Operations
 
On August 10, 2012, the Company entered into an agreement with Sinclair Pharmaceuticals Limited (“Sinclair”) to terminate, effective September 30, 2012, the distribution agreements relating to the promotion and sale of Xclair®, Numoisyn® Lozenges and Numoisyn® Liquid (collectively, the “ALIGN products”).
Product revenue, cost of goods sold and selling, general and administrative costs related to the promotion and sale of the ALIGN products have been reclassified from operating results from continuing operations to income from discontinued operations in the consolidated statement of operations for all periods presented as follows (in $000s): 
​ ​ ​
Year ended 
December 31, 
2014
 ​ ​
Year ended 
December 31, 
2015
 ​
Interest income
 ​ ​ ​ $ 29 ​ ​ ​ ​ $ — ​ ​
Income tax on discontinued operations
 ​ ​ ​ ​ (10) ​ ​ ​ ​ ​ — ​ ​
Net income from discontinued operations, net of tax
 ​ ​ ​ $ 19 ​ ​ ​ ​ $ — ​ ​
​
The assets and liabilities associated with product promotion and sales have been classified within assets and liabilities of discontinued operations in the accompanying consolidated balance sheets (in $000s):
     
December 31, 
2014
    
December 31, 
2015
  
Current assets of discontinued operations:      
Short term portion of minimum royalty arrangement receivable,
net
       $ 96         $ —    
Returns indemnification receivable
         75           75    
Total current assets of discontinued operations
         171           75    
Long-term assets of discontinued operations:      
Long-term portion of minimum royalty arrangement receivable,
net
         —           —    
Total assets of discontinued operations
       $ 171         $ 75    
 
     
December 31,
2014
    
December 31,
2015
  
Current liabilities of discontinued operations:      
Returns provision
       $ 75         $ 75    
Total current liabilities of discontinued operations
       $ 75         $ 75